RAPT Therapeutics (RAPT) to Release Earnings on Thursday

RAPT Therapeutics (NASDAQ:RAPT) is expected to be announcing its Q1 2025 earnings results before the market opens on Thursday, May 8th. Analysts expect RAPT Therapeutics to post earnings of ($0.31) per share for the quarter.

RAPT Therapeutics (NASDAQ:RAPT) last issued its earnings results on Thursday, March 6th. The company reported ($1.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.69). On average, analysts expect RAPT Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

RAPT Therapeutics Trading Down 11.1 %

Shares of NASDAQ RAPT opened at $0.81 on Wednesday. RAPT Therapeutics has a 12-month low of $0.75 and a 12-month high of $8.30. The company has a market cap of $107.19 million, a price-to-earnings ratio of -0.29 and a beta of -0.04. The stock’s 50 day simple moving average is $1.05 and its 200 day simple moving average is $1.27.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of RAPT Therapeutics in a research note on Monday, March 10th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $4.00.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.